Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Baxter
Harvard Business School
Express Scripts
Mallinckrodt

Last Updated: January 28, 2022

DrugPatentWatch Database Preview

Details for Patent: 8,158,645


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,158,645 protect, and when does it expire?

Patent 8,158,645 protects HYCAMTIN and is included in one NDA.

This patent has eighteen patent family members in sixteen countries.

Summary for Patent: 8,158,645
Title:Compound, corresponding compositions, preparation and/or treatment methods
Abstract: Disclosed is a novel crystalline form of topotecan monohydrochloride pentahydrate, which is a pentahydrate of 10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indo- lizino[1,2-b]quinoline-3,14(4H,12H)dione monohydrochloride, corresponding pharmaceutical compositions, methods preparation and/or use thereof to treat anti-viral and/or cancer-related diseases.
Inventor(s): Dell'Orco; Philip C. (King of Prussia, PA), Diederich; Ann Marie (King of Prussia, PA), Su; Qiaogong (King of Prussia, PA), Wood; Jeffery Lee (King of Prussia, PA)
Assignee: GlaxoSmithKline LLC (Philadelphia, PA)
Application Number:12/770,898
Patent Claim Types:
see list of patent claims
Composition; Compound; Process; Formulation;

Drugs Protected by US Patent 8,158,645

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis HYCAMTIN topotecan hydrochloride CAPSULE;ORAL 020981-001 Oct 11, 2007 RX Yes No ⤷  Sign up for a Free Trial ⤷  Sign up for a Free Trial Y ⤷  Sign up for a Free Trial
Novartis HYCAMTIN topotecan hydrochloride CAPSULE;ORAL 020981-002 Oct 11, 2007 RX Yes Yes ⤷  Sign up for a Free Trial ⤷  Sign up for a Free Trial Y ⤷  Sign up for a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Boehringer Ingelheim
Merck
Moodys
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.